Evaluation of safety and efficacy of Liv.52 GNX tablet in Alcoholic liver disease: A randomized comparative controlled clinical study

The Himalaya Drug Company0 个研究点目标入组 40 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1 Preferably Male patients aged more than 18 years to 70 years with diagnosis of symptomatic Alcoholic liver disease
•2 Patients who are presenting with one or more altered liver function parameters with a minimum consumption of alcohol for 3 times a week.
•3 Alcoholic, for at least a minimum period of 1 year.
•4 Clinically presenting with one or more clinical symptoms of Alcoholic liver disease like abdominal discomfort, anorexia, weakness, easy fatiguability etc.
•5 Willing to sign inform consent form and comply with the study procedure.

•1 Pregnant women, patients with severe hepatitis, patients with malignant jaundice
•2 Patients with other causes for acute hepatitis (drug-induced)
•3 Patients unwilling to provide informed consent or abide by the requirements of the study
•4 A known history or present condition of allergic response to any of the herbs or drugs
•5 Pre-existing systemic disease necessitating long-term medications.
•6 Genetic and endocrinal disorders.
•7 Has participated in a similar clinical investigation in the past four weeks.
•8 Has used a similar product in the past four weeks

发起方